Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks.
Neurofilament light chain level is a weak risk factor for the development of MS.
Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.
Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.
Is disability measured by FIM a predictor for successful self-intermittent catheterization in neurological patients?
Transfer of folate to the fetus.
Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis.
Neurotherapeutic Strategies for Multiple Sclerosis.
Differential diagnosis, discerning depression from cognition.
Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I.
Effect of fampridine on axonal excitability in multiple sclerosis.
Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.
Clusterin CSF levels in differential diagnosis of neurodegenerative disorders.
Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.
Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.
TRAIL gene expression analysis in multiple sclerosis patients.
NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.
The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis.
Immune cell-specific transcriptional profiling highlights distinct molecular pathways controlled by Tob1 upon experimental autoimmune encephalomyelitis.
Corrigendum.
Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results.
[MEDICAL CANNABIS].
Concomitant Guillain Barre Syndrome and Transverse Myelitis as Initial Neuropsychiatric Manifestation in a Case of Lupus: A Diagnostic Quandary.
Effects of Chronic Scopolamine Treatment on Cognitive Impairments and Myelin Basic Protein Expression in the Mouse Hippocampus.
Pages
« first
‹ previous
…
738
739
740
741
742
743
744
745
746
…
next ›
last »